Argenx weakness presents ‘attractive opportunity,’ says BofA

After an FDA report released earlier today indicated that the agency is evaluating the risk of severe worsening of chronic inflammatory demyelinating polyneuropathy with Vyvgart Hytrulo after the most recent FAERS update, BofA connected with Argenx (ARGX) management, who highlighted the most recent safety update presented at the American Academy of Neurology meeting. The firm highlighted that FAERS reports do not list a denominator to estimate the actual incidence of these cases and also tells investors that these reports “need to be adjudicated as we have seen misreporting with previous launches” and points out that newer drug launches often have outsized reporting of events as certain doctors tend to want to report with more frequency. Argenx remains one of the analyst’s top picks for 2025 with a Buy rating and $804 price target notes BofA, which sees any weakness in the stock today as “an attractive opportunity.”